---
name: ProBio
slug: probio
site: both
website_domain: probiocdmo.com
summary: ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization. Headquartered in United States.
tagline: End-to-end CDMO services for biologics and cell & gene therapy from discovery to commercialization
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: US
tier2_domain_verified: false
updated_at: 2026-06-11T03:11:18.711Z
services_count: 7
modalities_count: 7
indications_count: 1
locations_count: 6
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# ProBio

End-to-end CDMO services for biologics and cell & gene therapy from discovery to commercialization

Listed on cro.directory.

## Summary

ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization. Headquartered in United States.

## At a glance

- HQ country: US

## Services

- Immunogenicity Assays (ADA / NAb)
- Flow Cytometry Services
- Bioanalysis
- Protein Engineering
- In Vitro Pharmacology
- ICH Stability Studies
- Analytical Method Development & Validation

## Modalities

- Biologics (Other)
- Biologics (Monoclonal Antibodies)
- Vaccine
- mRNA
- Cell Therapy
- Gene Therapy
- AAV / Viral Vector Platform

## Indications

- Infectious Disease

## Locations

- Nanjing, Nanjing, China
- Shanghai, Shanghai, China
- Hong Kong, Hong Kong, China
- South Korea, South Korea
- Netherlands, Netherlands
- United States, United States

## Certifications

- NMPA; Identifier: National Medical Products Administration; Source: https://probiocdmo.com/
- EMA; Identifier: European Medicines Agency; Source: https://probiocdmo.com/
- FDA; Identifier: US Food and Drug Administration; Source: https://probiocdmo.com/

## Long description

ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization. The company specializes in:

**Core Capabilities:**
- **CGT Solutions:** Comprehensive CMC services for plasmid, viral vector, mRNA vaccine, and nucleic acid drugs, including cell banking, process development, characterization, validation, analytical method development, and stability studies
- **Biologics Discovery & Development:** Therapeutic antibody discovery, antibody engineering, and in vitro/in vivo pharmacology studies
- **GMP Manufacturing:** DNA-to-GMP material platform with stable cell line development, process development, analytical development, and clinical/commercial manufacturing using fed-batch and perfusion processes
- **Bioanalytical Services:** Advanced analytical capabilities including Biacore surface plasmon resonance (8k and T200), high-throughput screening (HTS iQue Screener), and flow cytometry (BD FACS Calibur with HTS loader)

**Regulatory Compliance:** GMP capacity meeting FDA, EMA, and NMPA requirements. The company has supported customers in obtaining more than 130 IND approvals since October 2017.

**Geographic Presence:** Established operations in the United States, Netherlands, South Korea, and China (Hong Kong, Shanghai, Nanjing) serving global customers across North America, Europe, and Asia Pacific.

ProBio's mission is "Innovation through Collaboration," focused on shortening development timelines, reducing R&D costs, and accelerating biologics and CGT programs from discovery to commercialization.

_Profile last updated: 2026-06-11T03:11:18.711Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.